Sorry, you need to enable JavaScript to visit this website.

RYBREVANT® for EGFR+ mNSCLC | RYBREVANT® (amivantamab-vmjw)

Banner Image

Treat metastatic non–small cell lung cancer (mNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations after chemotherapy that contains platinum.

RYBREVANT® is the first and only antibody treatment designed to target mNSCLC with EGFR exon 20 insertion mutations


40% of people treated with RYBREVANT® after chemotherapy that contains platinum saw their tumors disappear (3.7%) or get smaller (36%).

EGFR, epidermal growth factor receptor; mNSCLC, metastatic non–small cell lung cancer.

Discover the clinical benefits

Explore resources

There are resources available to help support you along the way.

Explore resources

Register Updates

Register for Updates

Sign up to receive the latest news and information about RYBREVANT®

Register here